REFERENCES
- Agrawal S., Marquet J., Delfau-Larue M. H., Copie-Bergman C., Jouault H., Reyes F., Bensussan A., Farcet J. P. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J. Clin. Invest 1998; 109: 1715, [CSA]
- Akbar A. N., Lord J. M., Salmon M. IFN-alpha and IFN-beta: A link between immune memory and chronic inflammation. Immunol. Today 2000; 21: 337, [INFOTRIEVE], [CSA], [CROSSREF]
- Atkins M. B., Robertson M. J., Gordon M., Lotze M. T., DeCoste M., DuBois J. S., Ritz J., Sandler A. B., Edington H. D., Garzone P. D., Mier J. W., Canning C. M., Battiato L., Tahara H., Sherman M. L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res 1997; 3: 409, [INFOTRIEVE], [CSA]
- Badovinac V. P., Porter B. B., Harty J. T. Programmed contraction of CD8(+) T cells after infection. Nat. Immunol 2002; 3: 619, [INFOTRIEVE], [CSA]
- Baeuerle P. A., Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13, [INFOTRIEVE], [CSA], [CROSSREF]
- Bajetta E., Del Vecchio M., Mortarini R., Nadeau R., Rakhit A., Rimassa L., Fowst C., Borri A., Anichini A., Parmiani G. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin. Cancer Res 1998; 4: 75, [INFOTRIEVE], [CSA]
- Barrat F. J., Cua D. J., Boonstra A., Richards D. F., Crain C., Savelkoul H. F., de Waal-Malefyt R., Coffman R. L., Hawrylowicz C. M., O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med 2002; 195: 603, [INFOTRIEVE], [CSA], [CROSSREF]
- Bernstein J. M., Broderick L., Parsons R. R., Bankert R. B. Human nasal polyp microenvironment maintained in viable and functional states as xenografts in SCID mice. Ann. Otol. Rhinol. Laryngol 2006; 115: 65, [INFOTRIEVE], [CSA]
- Bluestone J. A., Abbas A. K. Natural versus adaptive regulatory T cells. Nature Rev. Immunol 2003; 3: 253, [CSA], [CROSSREF]
- Broderick L., Yokota S. J., Reineke J., Mathiowitz E., Stewart C. C., Barcos M., Kelleher R. J., Jr., Bankert R.B. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells. J. Immunol 2005; 174: 898, [INFOTRIEVE], [CSA]
- Broderick L., Brooks S. P., Takita H., Baer A. N., Bernstein J. M., Bankert R. B. IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin. Immunol 2006; 118: 159, [INFOTRIEVE], [CSA], [CROSSREF]
- Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med 1999; 5: 919, [INFOTRIEVE], [CSA], [CROSSREF]
- Chahlavi A., Rayman P., Richmond A. L., Biswas K., Zhang R., Vogelbaum M., Tannenbaum C., Barnett G., Finke J. H. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res 2005; 65: 5428, [INFOTRIEVE], [CSA], [CROSSREF]
- Chen L. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity. Nature Rev. Immunol 2004; 4: 336, [CSA], [CROSSREF]
- Chiou S. H., Sheu B.-C., Chang W.-C., Huang S.-C., Hong-Nerng H. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J. Reprod. Immunol 2005; 67: 35, [INFOTRIEVE], [CSA], [CROSSREF]
- Coughlin C. M., Wysocka M., Trinchieri G., Lee W. M. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 1997; 57: 2460, [INFOTRIEVE], [CSA]
- Didenko V. V., Ngo H. N., Minchew C., Baskin D. S. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J. Neurosurg 2002; 96: 580, [INFOTRIEVE], [CSA]
- Finke J., Ferrone S., Frey A., Mufson A., Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today 1999; 20: 158, [INFOTRIEVE], [CSA], [CROSSREF]
- Gastman B. R., Atarshi Y., Reichert T. E., Saito T., Balkir L., Rabinowich H., Whiteside T. L. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356, [INFOTRIEVE], [CSA]
- Gollob J. A., Veenstra K. G., Parker R. A., Mier J. W., McDermott D. F., Clancy D., Tutin L., Koon H., Atkins M. B. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol 2003; 21: 2564, [INFOTRIEVE], [CSA], [CROSSREF]
- Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J. E., Roncarolo M. G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737, [INFOTRIEVE], [CSA], [CROSSREF]
- Hess S. D., Egilmez N. K., Shiroko J., Bankert R. B. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model. Cancer Gene Therapy 2001; 8: 371, [INFOTRIEVE], [CSA], [CROSSREF]
- Hess S. D., Egilmez N. K., Bailey N., Anderson T. M., Mathiowitz E., Bernstein S. H., Bankert R. B. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J. Immunol 2003; 170: 400, [INFOTRIEVE], [CSA]
- Hill H. C., Conway J. T. F., Sabel M. S., Jong Y. S., Mathiowitz E., Bankert R. B., Egilmez N. K. Cancer immunotherapy with interleukin-12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: Coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002; 62: 7254, [INFOTRIEVE], [CSA]
- Hogan R. J., Usherwood E. J., Zhong W., Roberts A. A., Dutton R. W., Harmsen A. G., Woodland D. L. Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol 2001; 166: 1813, [INFOTRIEVE], [CSA]
- Homann D., Holz A., Bot A., Coon B., Wolfe T., Petersen J., Dyrberg T. P., Grusby M. J., von Herrath M. G. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 1999; 11: 463, [INFOTRIEVE], [CSA], [CROSSREF]
- Kikuchi K., Neuwelt E. A. Presence of immunosuppressive factors in brain-tumor cyst fluid. J. Neurosurg 1983; 59: 790, [INFOTRIEVE], [CSA]
- Kullberg M. C., Hay V., Cheever A. W., Mamura M., Sher A., Letterio J. J., Shevach E. M., Piccirillo C. A. TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Europ. J. Immunol 2005; 35: 2886, [CSA], [CROSSREF]
- Leonard J. P., Sherman M. L., Fisher G. L., Buchanan L. J., Larsen G., Atkins M. B., Sosman J. A., Dutcher J. P., Vogelzang N. J., Ryan J. L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90: 2541, [INFOTRIEVE], [CSA]
- Liang L., Sha W. C. The right place at the right time: novel B7 family members regulate effector T cell responses. Curr. Opin. Immunol 2002; 14: 384, [INFOTRIEVE], [CSA], [CROSSREF]
- Liyanage U. K., Moore T. T., Joo H. G., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S., Linehan D. C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol 2002; 169: 2756, [INFOTRIEVE], [CSA]
- Malisan F., Testi R. GD3 ganglioside and apoptosis. Biochim. Biophys. Acta 2002; 1585: 179, [INFOTRIEVE], [CSA]
- Marrack P., Kappler J., Mitchell T. Type I interferons keep activated T cells alive. J. Exp. Med 1999; 189: 521, [INFOTRIEVE], [CSA], [CROSSREF]
- Masopust D., Vezys V., Marzo A. L., Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291: 2413, [INFOTRIEVE], [CSA], [CROSSREF]
- May M. J., Ghosh S. Signal transduction through NF-kappa B. Immunol. Today 1998; 19: 80, [INFOTRIEVE], [CSA], [CROSSREF]
- McKallip R., Li R., Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol 1999; 163: 3718, [INFOTRIEVE], [CSA]
- Mestas J., Huges C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol 2004; 172: 2731, [INFOTRIEVE], [CSA]
- Morford L. A., Dix A. R., Brooks W. H., Roszman T. L. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors. J. Neurosurg 1999; 91: 935, [INFOTRIEVE], [CSA]
- Motzer R. J., Rakhit A., Schwartz L. H., Olencki T., Malone T. M., Sandstrom K., Nadeau R., Parmar H., Bukowski R. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res 1998; 4: 1183, [INFOTRIEVE], [CSA]
- Nair R. E., Jong Y. S., Jones S. A., Sharma A., Mathiowitz E., Egilmez N. K. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J. Immunotherapy 2006; 29: 10, [CSA], [CROSSREF]
- Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med 2001; 194: 629, [INFOTRIEVE], [CSA], [CROSSREF]
- Nakamura O., Iwamori M., Matsutani M., Takakura K. Ganglioside GD3 shedding by human gliomas. Acta Neurochirurgica 1991; 109: 34, [INFOTRIEVE], [CSA], [CROSSREF]
- Park S. H., Kyin T., Bendelac A., Carnaud C. The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J. Immunol 2003; 170: 1197, [INFOTRIEVE], [CSA]
- Portielje J. E., Kruit W. H., Schuler M., Beck J., Lamers C. H., Stoter G., Huber C., de Boer-Dennert M., Rakhit A., Bolhuis R. L., Aulitzky W. E. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res 1999; 5: 3983, [INFOTRIEVE], [CSA]
- Radoja S., Saio M., Frey A. B. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J. Immunol 2001; 166: 6074, [INFOTRIEVE], [CSA]
- Rangarajan A., Weinberg R. A. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev. Cancer 2003; 3: 952, [CSA], [CROSSREF]
- Robertson M. J., Cameron C., Atkins M. B., Gordon M. S., Lotze M. T., Sherman M. L., Ritz J. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res 1999; 5: 9, [INFOTRIEVE], [CSA]
- Rook A. H., Wood G. S., Yoo E. K., Elenitsas R., Kao D. M., Sherman M. L., Witmer W. K., Rockwell K. A., Shane R. B., Lessin S. R., Vonderheid E. C. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902, [INFOTRIEVE], [CSA]
- Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., Kuniyasu Y., Nomura T., Toda M., Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev 2001; 182: 18, [INFOTRIEVE], [CSA], [CROSSREF]
- Sharpe A. H., Freeman G. J. The B7-CD28 superfamily. Nature Rev. Immunol 2002; 2: 116, [CSA], [CROSSREF]
- Shevach E. M. CD4+ CD25+ suppressor T cells: more questions than answers. Nature Rev. Immunol 2002; 2: 389, [CSA]
- Shevach E. M. Fatal attraction: tumors beckon regulatory T cells. Nature Med 2004; 10: 900, [INFOTRIEVE], [CSA]
- Shevach E. M. Regulatory/suppressor T cells in health and disease. Arthritis and Rheumatism 2004; 50: 2721, [INFOTRIEVE], [CSA], [CROSSREF]
- Siegal F. P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P. A., Shah K., Ho S., Antonenko S., Liu Y. J. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835, [INFOTRIEVE], [CSA], [CROSSREF]
- Sung C. C., Pearl D. K., Coons S. W., Scheithauer B. W., Johnson P. C., Zheng M., Yates A. J. Correlation of ganglioside patterns of primary brain tumors with survival. Cancer 1995; 75: 851, [INFOTRIEVE], [CSA], [CROSSREF]
- Triozzi P. L., Strong T. V., Bucy R. P., Allen K. O., Carlisle R. R., Moore S. E., Lobuglio A. F., Conry R. M. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Human Gene Therapy 2005a; 16: 91, [INFOTRIEVE], [CSA], [CROSSREF]
- Triozzi P. L., Allen K. O., Carlisle R. R., Craig M., LoBuglio A. F., Conry R. M. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin. Cancer Res 2005b; 11: 4168, [INFOTRIEVE], [CSA], [CROSSREF]
- Ullman K. S., Northrop J. P., Verweij C. L., Crabtree G. R. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Ann. Rev. Immunol 1990; 8: 421, [CSA], [CROSSREF]
- Uzzo R. G., Rayman P., Kolenko V., Clark P. E., Cathcart M. K., Bloom T., Novick A. C., Bukowski R. M., Hamilton T., Finke J. H. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J. Clin. Invest 1999; 104: 769, [INFOTRIEVE], [CSA]
- Van Herpen C. M. L., van der Laak J. A., de Vries I. J., van Krieken J. H., de Wilde P. C., Balvers M. G., Adema G. J., De Mulder P. H. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin. Cancer Res 2005; 11: 1899, [INFOTRIEVE], [CSA], [CROSSREF]
- Van Herpen C. M. L., Looman M., Zonneveld M., Scharenborg N., de Wilde P. C., van de Locht L., Merkx M. A., Adema G. J., de Mulder P. H. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin. Cancer Res 2004; 10: 2626, [INFOTRIEVE], [CSA], [CROSSREF]
- Von Herrath M. G., Harrison L. C. Antigen-induced regulatory T cells in autoimmunity. Nature Rev. Immunol 2003; 3: 223, [CSA], [CROSSREF]
- Wagener R., R. G., S. G., S. R., K. B., E. R. I. Ganglioside profiles in human gliomas: quantification by microbore high performance liquid chromatography and correlation to histomorphology and grading. ACTA Neurochir (Wien) 1999; 141: 1339, [CSA], [CROSSREF]
- Wang H. Y., Lee D. A., Peng G., Guo Z., Li Y., Kiniwa Y., Shevach E. M., Wang R. F. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004; 20: 107, [INFOTRIEVE], [CSA], [CROSSREF]
- Weinstock J. V., Blum A., Metwali A., Elliott D., Arsenescu R. IL-18 and IL-12 Signal Through the NF-kB Pathway to Induce NK-1R Expression on T Cells. J. Immunol 2003; 170: 5003, [INFOTRIEVE], [CSA]
- Williams S. S., Chen F. A., Kida H., Yokota S., Miya K., Kato M., Barcos M. P., Wang H., Alosco T., Umemoto T., Croy B. A., Repasky E. A., Bankert R. B. Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J. Immunol 1996; 156: 1908, [INFOTRIEVE], [CSA]
- Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766, [INFOTRIEVE], [CSA]
- Woo E. Y., Yeh H., Chu C. S., Schlienger K., Carroll R. G., Riley J. L., Kaiser L. R., June C. H. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol 2002; 168: 4272, [INFOTRIEVE], [CSA]
- Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 2005; 5: 263, [CSA], [CROSSREF]